Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Proof-of-Concept Study of GS-9876 in Active Rheumatoid Arthritis on Methotrexate
2016-001496-75Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing GS-9876 + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: Change from baseline in DAS28 (CRP) at Week 12. Started Sep 2016; status: completed.
02
Drugs
lanraplenib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-001496-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001496-75.